Open for inclusion

Cancer type Title Country
Bladder cancer A phase II single arm clinical trial of nivolumab (BMS936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent FI
Breast cancer A multicenter, multinational, Phase II study to evaluate Pertuzumab in combination with Trastuzumab and standard neoadjuvant Anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer NO
Breast cancer A Phase 1b Study to Evaluate safety and clinical activity of Pembrolizumab (MK-3475) in combination with Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) – (KEYNOTE 173) SE
Breast cancer A phase 1B study to evaluate safety anf clinical activity of pembrolozumab (MK-3475) in combination with chemotherapy as neoadjuvant treatment for trible negative breast cancer FI
Breast cancer A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Treated With Hormonal Treatment Backg DK
Breast cancer A Phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases treated with hormonl treatment backgr FI
Breast cancer A Phase II randomized, douple-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breats cancr subjects with bone metastases treated with hormonl treatment backgro FI
Breast cancer A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation NO
Breast cancer Intra-hepatic chemotherapy in patient with non-resectable liver mestastases from breast cancer. Only patients without extrahepatic disease are included DK
Breast cancer Intra-hepatic chemotherapy in patient with non-resectable liver metastases from breast cancer and limited extrahepatic disease DK
Breast cancer Phase Ib, open-label, multicenter dose-escalation study followed by an extension phase to evaluate the safety pharmacokinetics and activity of RO5479599 a glycoengineered antibody against HER3, administered incombination with pertuzumab and paclitaxel in DK
Cholangiocarcinoma A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of AmphinexTM induced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/ Cisplatin Chemotherapy in Patients with Advanced Inoperable Cholangioca NO
Colorectal cancer An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of Modufolin® in Combination with a Fixed Dose of 5-Fluorouracil (5-FU) alone or together with a Fixed Dose of Oxaliplatin or Irinotecan in Patients with Stage IV Colorectal Cancer NO
Colorectal cancer Effects of S-1 and Capecitabine in sombination with Oxaliplatine on the coronary artery blood flow in patients with metastatic gastrointestinal tract adenocarcinoma NO
Colorectal cancer Full dose monotherapy S-1 (followed by irinotecan) compared to reduced dose combination therapy (S-1/pxaliplatin followed by S-1/irinotecan) as initilal therapy for older patients with metastatic colorectal cancer FI
Colorectal cancer Open-label , single-arm, phase II study of bevacizumab (Avastin) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer FI
Colorectal cancer Potentially Resectable Metastatic Colorectal Cancer With Wild-type KRAS and BRAF: Alternating Chemotherapy Plus Cetuximab - A Randomised Phase II Trial NO
Colorectal cancer Treatment of Inoperable Colorectal Cancer With Electrochemotherapy Through an Endoscopic System DK
Gastric cancer A randomized phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumor (GIST) FI
Gastric cancer Everolimus and temozolmide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55% NO
Gastric cancer Pazopanib in advanced gastrointestinal stromal tumors refractory to imatinib and sunutinib. A Non-comparative phase II multicenter study study by the Scandinavian Sarcoma Group FI
Glioblastoma A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) NO
Glioblastoma Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide (KING) DK
HCC, Lung cancer, Melanoma A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab) in Advanced Solid Tumors NO
Head and Neck cancer ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group; EORTC protocol 1410-BTG/AbbVie protocol M14-483 FI
Hematological malignancies Dendritic cell-based active immunotherapy of patients with acute myeloid leukemia using autologous cells transfected with RNA encoding two different leukemia-associated antigens NO
Leukemia A multicenter open randomised phase II study of the efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) DK
Leukemia A Multicenter, Open-Label, Dose-Escalating Phase I Trial of the DNA-PK Inhibitor MSC2490484A in Subjects With Advanced Solid Tumors or Chronic Lymphocytic Leukemia DK
Leukemia A multicentre open randomized phase II study of the efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) DK
Leukemia A phase I multicenter open-label study of BGB324 as a single agent and in combination with cytarabine in patients with acute myeloid leukemia or high/intermediate (int-2) risk myelodysplastic syndrome wich overexpresses axl NO
Leukemia A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia NO
Leukemia A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years. NO
Leukemia A randomized, open label, phase 2 study of the selective inhibitor of nuclear export (sine) selinexor (kpt-330) versus specified physician’s choice in patients ≥ 60 years old with relapsed/refractory acute myeloid leukemia (aml) who are ineligible for int DK
Leukemia A safety and efficacy study of adding low dose pegylated IFN-alpha 2b to standard dose dasatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia DK
Lung cancer A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer NO
Lung cancer Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination with Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects with Solid Malignancies and Deregulated FGF Pathway Signaling DK
Lung cancer, Melanoma, Thyroid cancer Open label multicenter Phase I/II study of the safety and efficacy of PDR001 administered to patients with advanced malignancies NO
Lymphoma A phase 1/2 study of combination of pixantrone, etoposide, bendamustine and in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T- cell phenotype- The P(RE)BEN study FI
Lymphoma A Phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and, in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T-cell phenotype – The P[R]EBEN study DK
Lymphoma A Phase I/II Study of 177Lu-HH1 (Betalutin®) Radioimmunotherapy for Treatment of Relapsed Non-Hodgkin Lymphoma NO
Lymphoma A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma DK
Lymphoma A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL NO
Lymphoma Brentuxumab vedotin or B-CAP in treatment of older patients with newly diagnosed classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II- trial FI
Lymphoma Chemo-immunotherapy with early central nervous system (CNS) prophylaxis DK
Lymphoma Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal AntibodyKW-0761(mogamulizumab) in Subjects with Previously Treated Peripheral T-Cell Lymphoma (PTCL) DK
Lymphoma Open-label, uncontrolled phase II trial of intravenous PI3K inhibitor BAY-80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin´s lymphomas FI
Lymphoma Protocol I6F-MC-JJCA(c) A Phase 1 Study of LY3039478 in Patients with Advanced or Metastatic Cancer DK
Lymphoma Randomised phase II trial on primary chemotherapy with high-dose methtrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cell trans DK
Lymphoma Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized double-blinded Phase II trial
Lymphoma, Sarcoma Cross tumoral phase II clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET NO
Melanoma A phase 1 study to evaluate safety, feasibility and immunologic response of adoptive T cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma SE
Melanoma The Melanoma Goup Trial: TOL + vemurafenib followed by interferon + vemurafenib maintenance (BRAF-positive patients) or TOL followed by interferon maintenance (BRAF-negative patients) FI
Melanoma, Pancreatic cancer, Solide tumores A phase Ib/II open label, multicentre study of PDR001 in combination with MCS110 in patients with advanced malignancies FI
Meningioma Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group NO
MPNST A phase II study of pembrolizumab in patients with malignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgery NO
Multiple diagnosis A first-in-human, multicenter, open-label, multiple ascending dose Phase I study in patients with advanced solid tumors to determine the safety, pharmacokinetics and pharmacodynamics of intratumorally administered ADC-1013 SE
Multiple diagnosis A Multicenter, Open-Label, Dose-Escalating Phase I Trial of the DNA-PK Inhibitor MSC2490484A in Subjects With Advanced Solid Tumors or Chronic Lymphocytic Leukemia DK
Multiple diagnosis A phase I, open-label, multi-arm, multi-centre, multi-dose, dose escalation study of LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab, in patients with transdermally accessible tumours NO
Multiple diagnosis A phase I, open-label, multi-arm, multi-centre, multi-dose, dose escalation study of LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab, in patients with transdermally accessible tumours NO
Multiple diagnosis A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib NO
Multiple diagnosis Calcium Electroporation for the Treatment of Keloids DK
Multiple diagnosis Calcium Electroporation for Treatment of Cutaneous Metastases DK
Multiple diagnosis Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours DK
Multiple diagnosis, Solide tumores An Open-Label, Multicohort, Phase II study of Atezolizumab in Advanced Solid Tumors NO
Multiple diagnosis, Solide tumores An Open-Label, Multicohort, Phase II study of Atezolizumab in Advanced Solid Tumors NO
Multiple diagnosis, Solide tumores First –in human, dose-escalating safety study of tissue factor specific antibody drug conjugate(Humax-TF-ADC) in patients with locally advanced and/or metastatic solid tumors known to express tissue factor SE
Myeloma A phase 1/2 multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenaöodomide (Len) with or without dexametasone (Dex) in subjects newly diagnosed multiple myeloma (NDMM) FI
Myeloma Phase II study of carfilzomib-cyclophophamide-dexamethasone and high-dose melphalan followed by randomization between observation or maintenance with carfilzomib and dexamethasone in patients with relapsed multiple myeloma after high-dose melphalan with DK
Ovarian cancer A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies and Metastatic Breast Cancer DK
Ovarian cancer KCP-330-005A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients with Advanced Gynaecologic Malignancies DK
Ovarian cancer Niraparib and/or Niraparib-bevacizumab combination against bevacizumab alone in Women with platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer Part 1: AVANOVA1 and part 2: AVANOVA2 DK
Prostate cancer DC-005 Prostate NO
Prostate cancer Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (DUALIDES) FI
Solide tumores A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) NO
Solide tumores A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) NO
Solide tumores A first-in-human Phase 1 dose excalation study of SAR428926 in patients with advanced solid tumors DK
Solide tumores A First-in-human, Multicenter, Open-label, Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intratumorally Administered ADC-1013 DK
Solide tumores A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors” FI
Solide tumores A phase 1/2 study of safety and efficacy of ulocuplumab combined with nivolumab in subjects with advanced or metastatic solid tumors FI
Solide tumores A phase I/II , open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors FI
Solide tumores A Phase II, Open-label, Study in Subjects with BRAF V600EMutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combiantion Therapy of Dabrafenib and Trametinib SE
Solide tumores An open label, multicohort, phase II study of MPDL3280A in advanced solid tumors FI
Solide tumores An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors DK
Solide tumores An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors SE
Solide tumores An Open-label multicenter dose escalation phase 1 study with an expansion phase to evaluate safety pharmacokinetics and therapeutic activity of RO6895882 an immunocytokine consisting of a variant of interleukin-2 (IL-2v) targeting carcinoembryonic antigen DK
Solide tumores An open-label, multicenter, dose-escalation phase 1b study to investigate the safety, pharmacokinetics, phamacodynamics, and therapeutic activity of RO7009789 (CD40 agonist) in combination with MPDL3280A (anti-PD-L1) in patients with locally advancedand/o DK
Solide tumores An open-label, multicohort, phase II study of MPDL3280A in advanced solid tumors NO
Solide tumores An open-label, multicohort, Phase II study of MPDL3280A in advanced solid tumors DK
Solide tumores An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification FI
Solide tumores An open-level, multicentre, dose-escalation, phase I study with an expansion phase, to evaluate safety, pharmacokinetics and therapeutic activity of RO6895882, an immunocytokine, consisting of a variant of interleukin-2 (IL-2v) targeting carcinoembryonic FI
Solide tumores Dose-escalating safety trial of tissue factor specific antibody drug conjugate (Humax®-TF-ADC) in patients with locally advanced and/or metastatic solid tumors known to express tissue factor DK
Solide tumores Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers DK
Solide tumores HuMax®-TF-ADC Safety Study in Patients With Solid Tumors DK
Solide tumores MetAction: Actionable Target Identification for Palliative Systemic Therapy NO
Solide tumores Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy DK
Solide tumores Phase 1b, open-label, multi-center, dose-esalation study of the safety, pharmacokinetics and therapeutic activity of RO6895882, an immunocytokine, which consists of a variant of interleukin-2 (IL-2v) that targets carcinoembryonic antigen (CEA), and MPDL32 DK
Solide tumores Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients with Solid Cancer DK
Solide tumores Phase I dose-escalating study to evaluate the safety and tolerability of LiPlaCis (Liposomal Cisplatin formulation) in patients with advanced or refractory tumours DK
Solide tumores Safety and tolerability of single and repeated doses of ODM-203: an opel-label, non-randomized, uncontrolled, dose escalation, multicentre, first-in-human study in subjects with advanced solid tumors FI
Urothelial An exploratory Phase I Study with Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract SE